The Mumbai-based pharmaceutical multinational Cipla has received the regulator’s approval to import Moderna’s Covid-19 Vaccine for restricted emergency use in India, sources informed ANI.
Cipla/Moderna gets #DCGA (Drugs Controller General of India) nod for import of #COVID19 vaccine, Government to make an announcement soon: Sources to ANI pic.twitter.com/NJ62FvGCDc
— NewsMobile (@NewsMobileIndia) June 29, 2021
The company, on behalf of the US pharma major Moderna, has sought the Drugs Controller General of India (DCGI) nod for importing for and marketing authorization of its COVID-19 vaccines, sources informed ANI
According to sources, Cipla has filed an application recently seeking permission for import of Moderna COVID-19 vaccine referring to DCGI notices dated April 15 and June 1 stating that if the vaccine is approved by the USFDA for EUA, the vaccine can be granted marketing authorization without trial and assessment of safety data first 100 beneficiaries of vaccines shall be submitted before rolling out in immunization program.
Moderna’s method to protect against Covid-19 relies on messenger RNA (mRNA) to program cells to generate immunity to the coronavirus. The vaccine has shown more than 90 per cent efficacy in clinical trials in protecting against COVID-19.
(With ANI Inputs)